Bing

SEARCH HISTORY

Somaxon Pharmaceuticals Inc. (SOMX) soared last week after the FDA approved its Silenor ... Before the FDA approval, this was a $4.00 stock. It ran to $10.60 before closing at $8.25 last week as major profit taking came into play. Last week’s reaction ...
Investor Place · 3/22/2010
t=somx]SOMX[/url]) is a specialty pharmaceutical company focused ... In the meantime, all investors can do is wait. We expect little in stock price movement over the next few months. We are keeping our rating at Hold, and maintaining our $5 price target.
ZACKS · 9/26/2008
StocksHaven Investments news portal takes a closer look at Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX), which hopes its drug ... investment dictionary, stock research reports, conference calls, news feeds, mailing list, videos, press release capability ...
Press Release Point · 7/22/2009
More from Bing News
While SOMX announced on Tuesday that they had entered into a definitive merger agreement for PTX to acquire the company in a stock-for-stock transaction with a total equity value of $25 million the deal still needs to be approved by shareholders.
OTC Equity · 12/11/2012
View photo SOMX fell 0.6 percent to $3.29 yesterday and is down 26 percent in the last month. The stock attempted to rally in August after announcing a deal with Procter & Gamble to distribute its Silenor sleeping medicine, but it encountered a flood of ...
Yahoo Finance · 10/22/2010
Persistence has paid off for development-stage biotech company Somaxon Pharmaceuticals Inc. (SOMX). The company's insomnia drug candidate Silenor, which has been thrice at the FDA altar, finally won the regulatory approval Thursday, sending the …
Realtime Business News · 3/19/2010
SAN DIEGO, Oct. 11, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that its Board of Directors approved a 1-for-8 reverse stock split of its common stock and a …
Reuters · 10/11/2012
BOSTON (MarketWatch) — Somaxon Pharmaceuticals Inc. was the drug sector’s biggest decliner on Friday, with shares falling after the biotech group priced a public stock offering below Thursday’s closing price. Shares of Somaxon Pharmaceuticals …
Market Watch · ByVal Brickates · 11/19/2010
Wall Street ratings agencies set the tone for today's stock market. Sina Corp (SINA): The stock gets a Buy and $50 target price. Somaxon Pharmaceuticals (SOMX): The stock is begun favorably by both Oppenheimer (Outperform, $12 price objective) and ...
Minyanville · ByJustin Sharon · 4/8/2010
Stocks on the move are Arc Sight, Inc. (NASDAQ: ARST), ImmunoGen Inc. (NASDAQ: IMGN), J. Crew Group, Inc. (NYSE: JCG), Netezza Corporation (NYSE: NZ), 3PAR, Inc. (NYSE: PAR), Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), SunPower …
24/7 Wall ST · 8/27/2010